Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study-Reference-Cited by-同舟云学术

Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study

Published:2023-11-20 Issue:33 Volume:41 Page:5140-5150
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Duvivier Herbert L.¹,Rothe Michael²,Mangat Pam K.²^ORCID,Garrett-Mayer Elizabeth²^ORCID,Ahn Eugene R.³,Al Baghdadi Tareq⁴,Alva Ajjai S.⁵,Dublis Stephanie A.⁶,Cannon Timothy L.⁷^ORCID,Calfa Carmen J.⁸^ORCID,Li Rui⁹,Behl Deepti¹⁰^ORCID,Chiu Vi K.¹¹,Gold Philip J.¹²,Marr Alissa S.¹³^ORCID,Mileham Kathryn F.¹⁴^ORCID,Powell Steven Francis¹⁵^ORCID,Rodon Jordi¹⁶^ORCID,Thota Ramya¹⁷^ORCID,Grantham Gina N.²^ORCID,Gregory Abigail²^ORCID,Hinshaw Dominique C.²^ORCID,Halabi Susan¹⁸^ORCID,Schilsky Richard L.²^ORCID

Affiliation:

1. Cancer Treatment Centers of America—Atlanta, Part of City of Hope, Newnan, GA

2. American Society of Clinical Oncology, Alexandria, VA

3. Cancer Treatment Centers of America—Chicago, Part of City of Hope, Zion, IL

4. Michigan Cancer Research Consortium, IHA Hematology Oncology, Ypsilanti, MI

5. University of Michigan Rogel Comprehensive Cancer Center, Ann Arbor, MI

6. University of Michigan Health-West, Wyoming, MI

7. Inova Schar Cancer Institute, Fairfax, VA

8. Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL

9. Providence Cancer Institute, Providence Portland Medical Center, Portland, OR

10. Sutter Sacramento Medical Center, Sacramento, CA

11. The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA

12. Swedish Cancer Institute, Seattle, WA

13. University of Nebraska Medical Center, Omaha, NE

14. Levine Cancer Institute, Atrium Health, Charlotte, NC

15. Sanford Health, Sioux Falls, SD

16. Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX

17. Intermountain Healthcare, Murray, UT

18. Duke University Medical Center, Durham, NC

Abstract

#TAPUR results of pembrolizumab in various tumors with HTMB extend KEYNOTE-158 data that led to FDA approval in tumors with HTMB

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.23.00702

Reference25 articles.

1. Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

2. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

3. Palbociclib in Patients With Pancreatic and Biliary Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study

4. Palbociclib in Patients With Non–Small-Cell Lung Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study

5. Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Addressing Genetic Tumor Heterogeneity, Post-Therapy Metastatic Spread, Cancer Repopulation, and Development of Acquired Tumor Cell Resistance;Cancers;2023-12-29

2. Latest trends in cancer clinical trials using genomics;Journal of the Korean Medical Association;2023-12-10